The impact of endocrine therapy on patients with breast cancer: A review of the literature

Breast

Volumn 11, Issue 1, 2002, Pages 1-12

  Coster, S ^a   Fallowfield, L J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; FORMESTANE; GESTAGEN; GONADORELIN; MEGESTROL ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; STEROID HORMONE; TAMOXIFEN; TOREMIFENE; VOROZOLE;

ADRENERGIC SYSTEM; ADVANCED CANCER; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FEMALE SEXUAL DYSFUNCTION; GASTROINTESTINAL TOXICITY; GYNECOLOGIC DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; RANDOMIZATION; SOCIAL PSYCHOLOGY;

EID: 0036166279     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2001.0397     Document Type: Article

References (62)

1. A risk-benefit assessment of tamoxifen therapy
2. Tamoxifen and contralateral breast cancer
3. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward oestrogen replacement therapy
4. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia
5. New endocrine therapies for breast cancer
6. Letrozole (femara) versus tamoxifen: Preliminary data of a first-line clinical trial in post menopausal women with locally advanced or metastatic breast cancer
7. Neo-adjuvant treatment of post-menopausal breast cancer patients with letrozole (Femara): A randomised study versus tamoxifen
8. Living with advanced breast cancer: Development and application of a clinical checklist for patients on endocrine therapy
9. Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management, and relation to quality of life
10. Phase III trials of toremifene vs tamoxifen
11. Living with hormone therapy for advanced breast cancer: A European survey of oncologists' and nurses' perceptions
12. Impact of side-effects associated with endocrine treatments for advanced breast cancer: Clinician’s and patient’s perceptions
13. The MOS 36 item short form health survey (SF-36)
14. The Hospital Anxiety and Depression Scale
15. Manual for the functional assessment of cancer therapy (FACT) quality of life instrument (version 4)
16. Measuring the quality of life of cancer patients: The functional living index-cancer: Development and validation
17. The European Organisation for Research and treatment of Cancer breast cancer-specific quality of life questionnaire module: First results from a three-county field study
18. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B
19. Assessment of quality of life in breast cancer
20. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
21. Effect of early American results on patients in a tamoxifen prevention trial (IBIS)
22. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study
23. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
24. Cancer research adjuvant breast trial for patients under fifty
25. A randomised, double-blind, parallel-group trial to assess quality of life with arimidex alone, nolvadex alone, or arimidex and nolvadex in combination, when used as adjuvant treatment for breast cancer in postmenopausal women
26. Randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent Adjuvant Exemestane treatment with further Tamoxifen
27. Effect of Tamoxifen on sexual functioning in patients with breast cancer
28. Sexuality and chronic illness: A comprehensive approach
29. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors
30. Sexual functioning in women with breast cancer after treatment with adjuvant therapy
31. Quality of life and preferences for treatment following systematic adjuvant therapy for early stage breast cancer
32. Assessing problems of cancer patients: Psychometric properties of the cancer inventory of problem situations
33. The DSFI: A multidimensional measure of sexual functioning
34. The sexual activity questionnaire: A measure of women’s sexual functioning
35. Chemoprevention of Breast Cancer with Tamoxifen
36. Sexual behaviour in the human female
37. Relationships between psychological symptoms, somatic complaints and menopausal status
38. The relationship between tamoxifen, oestrogen, and depressive symptoms
39. The CES-D Scale: A self-report depression scale for research in the general population
40. Symptoms associated with tamoxifen treatment in postmenopausal women
41. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect?
42. Handbook for the IPAT depression scale
43. Manual for the state-trait anxiety inventory (form Y)
44. The prevalence of menopausal symptoms in patients treated for breast cancer
45. Use of the General Health Questionnaire in clinical work
46. Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer?
47. The prevalence of psychiatric disorder among cancer patients
48. Comparative studies of psychological function in patients with advanced cancer. II. Interviewer-rated current and past psychological symptoms
49. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
50. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
51. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist
52. Screening for psychiatric morbidity in patients with advanced breast cancer. Validation of two self-report questionnaires
53. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
54. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment
55. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer
56. Conceptualisation and measurement of health for adults
57. The DSFI: A multidimensional measure of sexual functioning
58. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
59. Assessing quality of life in cancer patients
60. Responsiveness of a single-item indicator versus a multi-item scale; assessment of emotional well-being in an international adjuvant breast cancer trial
61. A comparison of two quality-of-life questionnaires for cancer clinical trials: The functional living index-cancer (FLIC) and the quality of life questionnaire core module (QLQ-C30)
62. Quality of life in breast cancer adjuvant therapy: Validation and pilot testing of a combination of questionnaires